129Xe Hyperpolarized

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
86	肺動脈性肺高血圧症	3

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

trials per page:

Showing 1 to 3 of 3 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04778046 (ClinicalTrials.gov)	February 15, 2023	26/2/2021	Pulmonary Hypertension SOLAR	Defining a Noninvasive Signature for Pulmonary Vascular Remodeling in Group 3 PH	Interstitial Lung Disease;COPD;Pulmonary Arterial Hypertension	Drug: Hyperpolarized 129Xe	Bastiaan Driehuys	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	United States
2	NCT05339386 (ClinicalTrials.gov)	August 29, 2022	13/4/2022	Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension	Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Hyperpolarized Xe129	University of Kansas Medical Center	American Heart Association	Recruiting	18 Years	N/A	All	22		United States
3	NCT04991454 (ClinicalTrials.gov)	September 1, 2021	7/7/2021	Xenon MRI Pulm Hypertension	Xenon MRI in Pulmonary Hypertension	Pulmonary Hypertension;Pulmonary Arterial Hypertension	Drug: 129Xe Hyperpolarized	Bastiaan Driehuys	NULL	Recruiting	18 Years	75 Years	All	60	Phase 2	United States

First Previous1Next Last